TAA/ecdCD40L oncolytic virus
US10130667B1 · kind B1 · utility
0Cited by
0References
3Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 15, 2016 |
| Grant date | Nov 20, 2018 |
| Priority date | — |
| Expiry date | May 18, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y305/04001
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a vaccine comprising the insertion of three genes, the TAA/ecdCD40L EA1 and CDA, driven by promoters L-plastin/cytosinedeaminase and CMV as a three gene, three transcription unit oncolytic virus as a conditionally replication competent adenoviral vector which replicates only in tumor cells. In these transcription units, the E1A gene of the adenoviral vector as well as the cytosine deaminase gene are under the control of the L-plastin promoter, while the TAA/ecdCD40L transcription unit is under control of a the CMV promoter.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.